30
C. Salomé et al. / Chemistry and Physics of Lipids 188 (2015) 27–36
temperature (16 h). The reaction mixture was concentrated under
vacuum and the crude was purified by chromatography on silica
gel using cyclohexane/EtOAc (100/0 to 50/50) as eluent to obtain
15 mg of DOG-PPh3 (4) as a colorless oil (62%); 1H NMR (400 MHz,
was mixed with an aqueous solution (1 mL) containing cystamine
dihydrochloride (107 mg, 0.47 mmol) and Et3N (309 L,
m
2.10 mmol). The reaction proceeded at room temperature over-
night with stirring. The white solid was filtered and washed with
water and EtOH to obtain N,N'-(disulfanediylbis(ethane-2,1-diyl))
bis(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentana-
mide) (7) as a white solid (250 mg; 87%); 1H NMR (400 MHz,
CDCl3): d 8.10 (dd, 1H, J = 8.0, 3.6 Hz, H of C6H3), 7.81 (dd, 1H, J = 8.0,
1.5 Hz, H of C6H3), 7.48-7.44 (m,1H, H of C6H3), 7.38-7.24 (m,10H, H
of C6H5), 6.65-6.59 (br s, 1H, NH), 5.41-5.32 (m, 4H), 3.76 (s, 3H,
OCH3), 3.68-3.41 (m, 25H, 11CH2O, CH2N and (CH2)2CHO), 2.08-
1.94 (m, 8H, 4CH2), 1.62-1.51 (m, 4H), 1.38-1.20 (m, 44H), 0.81 (t,
DMSO-d6):
d 8.08-8.04 (br m, 2H), 6.48 (s, 2H), 6.43 (s, 2H), 4.39-
4.34 (m, 2H), 4.22-4.17 (m, 2H), 3.42-3.35 (m, 2H), 3.19-3.14 (m,
2H), 2.88-2.81 (m, 6H), 2.64 (d, J = 12.9 Hz, 2H), 2.13 (t, J = 7.3 Hz,
4H), 1.72-1.53 (m, 8H), 1.40-1.34 (m, 4H); 13C NMR (100 MHz,
6H, J = 7.0 Hz, 2CH3); 13C NMR (100 MHz, CDCl3):
d 14.1 (2CH3), 22.7,
27.2, 29.3, 29.5, 29.5, 29.6, 29.6, 29.7, 29.8, 30.1, 32.6 (29CH2), 39.8
(CH2CH2N), 52.2 (OCH3), 69.6 (11CH2O), 70.3, 70.5, 70.6, 70.7, 70.9,
71.5, 71.7, 77.9 (CHCH2O), 126.7, 126.8, 128.6, 128.7, 129.0, 129.8,
129.9, 132.8, 133.8, 134.0 (10CH), 137.2, 137.3, 137.4, 141.3, 142.6
(4C), 158.7 (C(O)NH), 166.4 (C(O)OMe); HRMS (ESI) m/z calcd for
DMSO-d6):
d 25.7, 28.5, 28.7, 35.6, 37.8, 38.3, 40.3, 55.9, 59.7, 61.5,
163.2, 172.7.
2.2.7. N-(2-(2-(2-(2-azidoethoxy) ethoxy) ethoxy) ethyl)-5-(6)-
(tetramethylcarboxyrhodamine (TAMRA-N3,8)
C
68H108NO9PH+ 1114.7834; found 1114.7856.
To a solution of 5-(6)-TMCR (43 mg, 0.10 mmol) in anhydrous
2.2.4. Preparation of 3,4-dibromo-1-((Z)-14-((Z)-octadec-9-en-1-
yloxy)-3,6,9,12,16-pentaoxatetratriacont-25-en-1-yl)-1H-pyrrole-
2,5-dione (5)
CH2Cl2 (3 mL), DIEA (87 mL, 0.50 mmol) and PyBOP (63 mg,
0.12 mmol) were added. The resulting mixture was stirred for
10 min to get the corresponding activated ester. Then 11-azido-
Dibromomaleic acid (2.5 mg, 9.11
m
mol) and DCC (2 mg,
3,6,9-trioxaundecan-1-amine (22 mL, 0.11 mmol) solubilized in
9.54 mol) were stirred in CH2Cl2 (2.5 mL) at room temperature
m
anhydrous CH2Cl2 (3 mL) were added to the above-mentioned
solution. The resulting mixture was stirred at room temperature
(3 h) protected from light. Then the solution was concentrated
under vacuum and the crude was purified on silica gel using
CH2Cl2/MeOH (100/0 to 80/20) to give 53 mg (84%) of 8 as a purple
(1 h) for activation. A CH2Cl2 solution of DOG-PEG4-NH2 (1) (7 mg,
0.01 mmol) was added and the solution was stirred at room
temperature (16 h). The volatiles were evaporated and acetic acid
(4 mL) was added. Then, the solution was stirred at reflux (16 h).
Acetic acid was evaporated under vacuum and the residue was
purified by chromatography on silica gel using cyclohexane/EtOAc
(100/0 to 50/50) as eluent to obtain 7 mg (60%) of DOG-DBM (5) as
solid; 1H NMR (300 MHz, CDCl3):
d 8.52-8.48 (br s, 0.4H), 8.19-8.09
(m, 0.8H), 8.03-7.98 (m, 0.4H), 7.70-7.64 (br m, 1.2H), 7.54-7.50 (br
m, 1H), 7.21-7.15 (m, 2.2H), 6.79 (t, J = 10.3 Hz, 1H), 6.51-6.45 (m,
a colorless oil; 1H NMR (400 MHz, CDCl3):
d
5.35-5.32 (m, 4H), 3.79
3H), 3.72-3.58 (m, 14H), 3.37-3.33 (m, 2H), 3.05-3.07 (m, 12H); 13
C
(t, 2H, J = 5.2 Hz), 3.67-3.38 (m, 21H), 2.03-1.95 (m, 8H), 1.53-1.49
NMR (75 MHz, DMSO-d6), d (ppm): 29.7, 40.0, 40.1, 40.4, 50.6, 50.7,
(m, 4H), 1.42-1.15 (m, 44H), 0.86 (t, 6H, J = 6.7 Hz); 13C NMR
69.6, 69.7, 69.8, 69.9, 70.0, 70.1, 70.2, 70.3, 70.41, 70.46, 70.53,
70.56, 70.6, 97.2, 97.4, 111.0, 111.13, 111.14, 111.19, 111.30, 111.34,
111.35, 117.9, 124.4, 125.3, 125.90, 125.96, 126.0, 126.96, 126.98,
127.9, 128.2, 128.3, 128.6, 130.0, 130.3, 132.0, 136.1, 142.2, 154.5,
154.6, 155.1, 154.2, 166.4, 169.3, 169.4; LRMS calcd for C33H39N6O7
631.3; found 631.3.
(100 MHz, CDCl3): d 14.1, 16.8, 22.7, 26.1, 26.2, 27.2, 29.3, 29.5, 29.5,
29.6, 29.7, 29.8, 30.1, 31.9, 32.6, 39.0, 67.5, 70.1, 70.6, 70.6, 70.6, 70.7,
70.8, 70.9, 71.5, 71.7, 77.9, 129.4, 129.8, 129.9; HRMS (ESI) m/z calcd
for C51H91Br2NO8H+ 1004.5 [79Br, 79Br], 1006.5 [79Br, 81Br], 1008.5
[
[
81Br, 81Br]; found 1004.4 [79Br, 79Br], 1006.4 [79Br, 81Br], 1008.4
81Br, 81Br].
2.3. Liposomes preparation and characterization
2.2.5. Preparation of N-(2-(2-(2-(2-azidoethoxy) ethoxy) ethoxy)
ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)
2.3.1. SUVs formation
pentanamide (Biotin-N3, (6)) (Kottani et al., 2006)
Liposomes were prepared by mixing, in a round-bottom flask,
phospholipids (PC, PG), and cholesterol (80/20/50 molar ratio) in
chloroform/methanol 9/1 with the appropriate amount of anchors
(1, 2.5, 5 and 10 mol% for the initial experiments, then 5 mol% for
further experiments with an adjustment of the PC concentration).
After solvent evaporation under high vacuum (45 min), the
resulting dried lipid film was hydrated by vortex mixing (5 min)
after addition of 1 mL of buffer (100 mM NaCl, 10 mM Hepes, pH
Biotin-OSuc (14) (187 mg, 0.55 mmol) was completely dissolved
in DMF (5 mL) with gentle warming. After slowly cooling the
solution to room temperature without recurring precipitation, the
11-azido-3,6,9-trioxaundecan-1-amine (Borcard et al., 2011)
(109 mg, 0.50 mmol) was added. The reaction proceeded at room
temperature overnight with stirring and the reaction products
were concentrated under vacuum. The remaining solid was
triturated in CH2Cl2/Et2O (30/70) solution and the white solid
was filtered to obtain N-(2-(2-(2-(2-azidoethoxy) ethoxy) ethoxy)
ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) penta-
7.4) to get a final concentration of 10 mmol of total phospholipids
per mL. The resulting suspension was sonicated at 25 ꢂC for 45 min
under a continuous flow of argon, using a 3 mm diameter probe
sonicator (Vibra Cell, Sonics and Material Inc., Danbury, CT) at
300 W. The small unilamellar vesicle (SUV) suspensions were
finally centrifuged for 10 min to remove the titanium dust
originating from the probe. Blank liposomes were only composed
of PC/PG/Chol (80/20/50 molar ratio) without anchor.
namide (6) (219 mg; quant.); 1H NMR (300 MHz, DMSO-d6):
d 6.43-
6.38 (s, 1H, NH), 6.37-6.34 (s, 1H, NH), 4.33-4.25 (m, 1H), 4.12-4.09
(m, 1H), 3.62-3.34 (m, 12H), 3.12-3.08 (m, 1H), 2.89-2.78 (m, 4H),
1.55-1.19 (m, 6H); 13C NMR (100 MHz, CDCl3):
d 25.6, 28.0, 28.1,
35.9, 39.2, 40.5, 50.7, 55.5, 60.3, 61.8, 70.0, 70.1, 70.4, 70.5, 70.6,
163.9, 173.5; LRMS (ESI) m/z calcd for C18H32N6O5SH+ 445.2; found
445.2.
2.3.2. PC assay
The PC content of liposome suspension was quantified using an
2.2.6. Preparation of N,N0-(disulfanediylbis(ethane-2,1-diyl))bis(5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamide) (7)
In accordance to a described procedure (Wang et al., 2012),
Biotin-OSuc (14) (300 mg, 0.87 mmol) was completely dissolved in
DMF (3 mL) with gentle warming (40 ꢂC). After slowly cooling the
solution to room temperature without recurring precipitation, it
enzymatic assay with a commercial test kit (AssayTM Phospholipid,
Wako Chemicals GmbH, Neuss, Germany). 5 or 10
suspensions were distributed in triplicate in a 96-well microplate
before adding 250 L of phospholipid B reagent solution, prepared
mL of liposome
m
according to the manufacturer’s instructions. The plates were then
incubated at 37 ꢂC for 10 min. A blue color appeared, in presence of